CTIM-20. PHASE I STUDY OF IBRUTINIB WITH RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

BACKGROUND: Glioblastoma is a devastating disease that is notoriously resistant to current therapies, leading to dismal patient outcomes and a median survival of just 14.6 months. A major problem in glioblastoma treatment is the inability to effectively target the cell population that gives rise to...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Rauf, Yasmeen, Peereboom, David, Fallah, Jaleh, Schilero, Cathy, Lackner, Pamela, Stevens, Glen, Ahluwalia, Manmeet
Format: Artigo
Language:Inglês
Published: Oxford University Press 2020
Subjects:
Clinical Trials: Immunologic
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650328/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.154
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items